media – Page 302 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

FIME 2024

Name：FIME 2024 Time: June 19-21, 2024 Official Website: https://www.fimeshow.com/en/home.html Venue: Miami Beach Convention Center City: Miami / USA Product categories: Medical equipment: laboratory supplies、operating room equipment,、medical consumables、orthopedic products、medical imaging equipment、ophthalmic equipment、therapeutic instruments and accessories、 biochemical and inspection equipment、detection、analysis and diagnosis instruments and accessories、electronic medical instruments and medical furniture. Medical supplies: auxiliary supplies for the disabled、nursing and rehabilitation instruments、monitoring instruments、plastic surgery equipment、dental equipment cleaning disinfection and sterilization products、 medical packaging、home care、cotton fabrics、medicines and nutrition and health products disposable products. About FIME: FIME is the largest medical specialty show in the southeastern United States. The feature of the exhibition is both regional and international. In addition to exhibitors and professional buyers mainly from Florida, the exhibition has attracted a large number of exhibitors and professional buyers from Latin American countries by taking advantage of the advantageous geographical location of the exhibition city adjacent to the Caribbean Sea. A large number of products and equipment are ...
- Source: drugdu
- 613
- December 20, 2023
Smartwatches prove effective in detecting heart arrhythmias in children

A recent study published in the journal Communications Medicine discusses how smartwatches can facilitate the diagnosis of arrhythmias in children. Background Smartwatches and other wearable devices are becoming increasingly popular and allow users to constantly monitor their health, leading to their value for medical diagnosis becoming well-recognized. While the utility of these devices for adults has been widely researched, including for cardiac health monitoring and reducing the time needed to detect symptomatic rhythms, little is known about how they can be used to monitor child health indicators. Palpitations and abnormalities in cardiac rhythms are a leading cause of referrals in pediatric cardiology. However, existing non-invasive methods like patch rhythm monitors are not always effective in diagnosing arrhythmias, as symptoms often present infrequently, and children cannot wear monitors for as long as adults. Invasive methods such as implantable loop monitors (ILR) allow long-term monitoring. However, this approach may not be ideal ...
- Source: drugdu
- 171
- December 20, 2023
Fluorescence Microscopy Combined with AI Enables Detection of Tumors at Early Stage

Detecting cancer in the body or monitoring it during therapy is typically a time-consuming process, often conducted in later phases when signs become obvious. Researchers engaged in cancer research are continuously seeking reliable and sensitive techniques to detect a developing tumor at a very early stage and to closely monitor the success or failure of cancer therapy. Therefore, a breakthrough in early cancer diagnosis is a significant advancement. Researchers have now achieved a breakthrough with the development of a test for early diagnosis of cancer. Researchers at the Paul Scherrer Institute (Würenlingen, Switzerland) have demonstrated that changes in the organization of the cell nucleus of certain blood cells can reliably indicate the presence of a tumor in the body. Using fluorescence microscopy, the team examined the chromatin of these blood cells – DNA packaged into a complex structure. They analyzed about 200 different characteristics, including the external texture, the packing ...
- Source: drugdu
- 158
- December 20, 2023
Illumina’s Antitrust Battles to End With Divestiture of Cancer Test Maker Grail

Illumina has decided against further appeals of U.S. and European antitrust litigation challenging its acquisition of liquid biopsy company Grail. Illumina expects to have terms of the divestiture set by the end of the second quarter of 2024. By FRANK VINLUAN Illumina is done fighting in the courts to keep cancer-detection company Grail. The gene-sequencing giant had previously pledged to divest Grail if it did not win either the U.S. or European appeals of anti-trust cases challenging the acquisition. A U.S. appeals court came down against the Federal Trade Commission’s case on Friday, but in a narrow way that hardly handed Illumina a clear victory. After reviewing the decision, Illumina said Sunday that it has decided against further litigation. The company will divest Grail. The planned divestiture is the latest step in a journey that started within Illumina. Grail began as research within the San Diego company. Grail spun out ...
- Source: drugdu
- 145
- December 20, 2023
Point Bio Prostate Cancer Therapy Meets Phase 3 Goal, But Results Still Disappoint

Despite achieving its Phase 3 study’s main goal, the results for Point Biopharma’s therapy are short of what Novartis radiopharmaceutical Pluvicto achieved in a similarly designed clinical trial. Nevertheless, the data readout should clear the way for Eli Lilly to complete its $1.4 billion acquisition of Point. By FRANK VINLUAN A Point Biopharma Global cancer therapy key to a $1.4 billion Eli Lilly M&A deal has met the main goal of its pivotal clinical trial in prostate cancer. But the results raise questions about how well the drug will match up against a radiopharmaceutical marketed by Novartis. The Point drug, PNT2002, is also a radiopharmaceutical. It offers targeted delivery of a radioactive particle by linking it to a ligand that targets PSMA, a protein abundant on the surface of prostate cancer cells. The open-label Phase 3 study evaluated the Point radiopharmaceutical in patients with cases of prostate cancer that has ...
- Source: drugdu
- 178
- December 20, 2023
Chilean President Gavriel Borich Meets with Yin Weidong, Chairman, President and CEO of SINOVAC

On December 12, 2023, local time, Chilean President Gavriel Borich met with Yin Weidong, Chairman, President and CEO of SINOVAC, and his delegation at the Presidential Palace. The two sides reached an agreement on the localization of vaccine production and cooperation in the research and development of health products, and the Chilean government will strongly support SINOVAC’s project promotion in the region. President Borich began by recalling his successful visit to China not long ago, emphasizing that when he met with President Xi Jinping, they jointly identified the need to further deepen cooperation in the health sector among the many bilateral cooperation between China and Chile. He also indicated that the Chilean government has set the strategic goal of developing vaccine R&D and industrialization in Chile. Chairman Yin Weidong responded, “His Excellency the President’s visit to China was indeed a great success, and the charisma you displayed attracted many Chinese ...
- Source: drugdu
- 160
- December 20, 2023
CanSino Bio and SPIMACO Signed a Cooperation Agreement on Innovative Vaccines, Continuing to Deepen the Comprehensive Strategic Partnership

Recently, China-Saudi Arabia Investment Conference was held in Beijing. As a representative of China’s innovative vaccine enterprises, CanSino Bio signed a vaccine cooperation framework agreement with SPIMACO, a Saudi Arabian pharmaceutical manufacturing company, at the Major Investment Collective Signing Ceremony, in which the two parties will cooperate in the commercialization of innovative vaccines, joint R&D and clinical research, as well as localized production. According to the agreement, the cooperation will focus on promoting the entry of CanSino Bio’s quadrivalent conjugate vaccine Manhexin® into Saudi Arabia and other markets in the Middle East and North Africa region. In Saudi Arabia, the quadrivalent conjugate vaccine has been included in the country’s childhood immunization program, and there is a strong demand for a quadrivalent conjugate vaccine with longer-lasting immunoprotection effect and higher safety in the local market. Post-marketing data shows that Mannhexin®, a quadrivalent conjugate vaccine from CanSino Bio, has a very impressive ...
- Source: drugdu
- 156
- December 20, 2023
GSK tees up AstraZeneca rivalry with positive Jemperli-Zejula readout in endometrial cancer

On a mission to grow in oncology, GSK has more positive data to report in endometrial cancer. This time, the company is touting results for its PD-1 inhibitor Jemperli and PARP inhibitor Zejula, which could become a threat to a rival therapy at AstraZeneca. Adding Jemperli and Zejula to chemotherapy significantly extended the time before tumor progression or death in patients with primary advanced or recurrent endometrial cancer that’s mismatch repair proficient or microsatellite stable (pMMR/MSS), GSK said Monday. The results came from the second part of the phase 3 RUBY trial. The trial also showed that the Jemperli-Zejula-chemo regimen was better at delaying disease worsening than chemo alone in the overall population, regardless of genetic stability. But GSK appears to think that the combo has more value in the pMMR/MSS subgroup. Patients with pMMR/MSS endometrial cancer have few treatment options, Hesham Abdullah, GSK’s head of oncology R&D, said in ...
- Source: drugdu
- 249
- December 20, 2023
Activist shareholders urge drugmakers to re-evaluate patent strategies, human rights policies

Over the years, shareholders at the Interfaith Center on Corporate Responsibility (ICCR) have repeatedly voiced concerns on a variety of subjects to top pharma companies. Now, as 2023 comes to a close, the group is taking pharma giants to task over their patenting strategies and potential human rights shortfalls. In proposals to AbbVie, Eli Lilly, Gilead, Johnson & Johnson, Merck and Pfizer, the group is pushing the companies to review how add-on patents for medicines can affect patient access. Additionally, Bristol Myers Squibb, Pfizer and Eli Lilly face calls to review and update their human rights policies. While ICCR has voiced pharma-related complaints plenty of times in the past, its proposals haven’t been met with much enthusiasm by the companies’ larger pools of shareholders. In 2019, for instance, investors at several large pharma companies rejected the group’s proposals to study the potential link between CEO pay and drug prices. In ...
- Source: drugdu
- 143
- December 20, 2023
Artificial Intelligence workplan to guide use of AI in medicines regulation

EMA and the Heads of Medicines Agencies (HMAs) have published an Artificial Intelligence (AI) workplan to 2028, setting out a collaborative and coordinated strategy to maximise the benefits of AI to stakeholders while managing the risks. The workplan will help the European medicines regulatory network (EMRN) to embrace the opportunities of AI for personal productivity, automating processes and systems, increasing insights into data and supporting more robust decision-making to benefit public and animal health. The AI workplan, prepared under the joint HMA-EMA Big Data Steering Group (BDSG), ensures the EMRN remains at the forefront in benefiting from AI in medicines regulation. The workplan was adopted by EMA’s Management Board at its December meeting. The field of AI is developing swiftly. Pharmaceutical companies increasingly use AI-powered tools in research, development and monitoring of medicines. National competent authorities are responding to the new opportunities and challenges by starting to use and develop ...
- Source: drugdu
- 143
- December 20, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.